Prospective study of the efficacy and safety of mycophenolate mofetil in patients with noninfectious uveitis and scleritis

Kiuchi Yoshiaki0 sites10 target enrollmentJune 9, 2022

Overview

No summary available.

Registry

who.int

Start Date

June 9, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Kiuchi Yoshiaki

•1\) Age at the time of consent acquisition is 18 years or older
•2\) Patients who can go to the outpatient clinic every 4 to 12 weeks after the start of administration
•3\) Patients who have written consent to participate in this study
•4\) Non\-infectious uveitis (intermediate, anterior intermediate, posterior, panuveitis) with a history of at least one eye
•5\) At least one eye with active eye inflammation for 90 days or more, SUN criteria, over 2 cells in the anterior chamber, over 2 vitreous opacity, retinal choroidal lesions
•6\) Patients who are visiting our hospital for at least one of the following.
•If there is an activity of eye inflammation even after administration of prednisolone, equivalent to 1
•mg/ kg, for 4 weeks.
•When the anti\-inflammatory effect is obtained by oral prednisolone treatment equivalent to 0\.5\-1mg/ kg and the relapse of inflammation due to the gradual decrease in oral administration is within 90 days before registration.
•If oral steroids are more than 10 mg/day are required 90 days before registration.

•1\) Infectious uveitis
•2\) Patients who cannot see through the fundus due to binocular cataract, corneal opacity, post\-iris adhesion, etc.
•3\) Chronically low intraocular pressure in both eyes, IOP less than 5 mmHg, 3 months
•4\) Patients who underwent endovascular surgery within 3 months before the start of administration of this drug.
•5\) Patients who received immunosuppressive agents other than steroids within 12 months before the start of administration of this drug.
•6\) Patients positive for hepatitis virus and tuberculosis syphilis.
•7\) In patients with severe renal disease, serum Cr 1\.5 mg / dL or higher or CKD stage 3b or higher.
•8\) Patients with systemic autoimmune disease.
•9\) Patients with the following complications, Liver disease, mental illness, seizure and paroxysmal disease, heart disease due to other causes.
•10\) Patients who have had serious side effects with immunosuppressants in the past.